CHAPEL HILL, N.C.--(BUSINESS WIRE)--Cempra Pharmaceuticals today announced the publication of new research in the May issue of Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology, demonstrating that its lead compound, CEM-101, is active in vitro against six clinically important human Mycoplasma and Ureaplasma species. The findings suggest that the antibiotic may have clinical utility across a range of difficult-to-treat infections, and that further investigations are warranted.
